Exodus Point Capital Management, LP Precision Biosciences Inc Transaction History

Exodus Point Capital Management, LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$0.97 - $45.0 $88,669 - $4.11 Million	91,412 New	91,412 $109,000
Q2 2022 Aug 19, 2022	SELL	$1.15 - $3.34 $24,657 - $71,612	-21,441 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$2.96 - $7.76 $63,465 - $166,382	21,441 New	21,441 $66,000
Q4 2021 Feb 11, 2022	SELL	$7.4 - $11.66 $80,600 - $127,000	-10,892 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$9.18 - $14.15 $123,287 - $190,034	-13,430 Reduced 55.22%	10,892 $126,000
Q2 2021 Aug 16, 2021	BUY	$8.07 - $12.52 $196,278 - $304,511	24,322 New	24,322 $305,000
Q3 2020 Nov 16, 2020	SELL	$4.65 - $8.73 $204,613 - $384,146	-44,003 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$4.66 - $8.7 $205,053 - $382,826	44,003 New	44,003 $367,000
Q4 2019 Feb 14, 2020	SELL	$6.32 - $19.66 $191,217 - $594,832	-30,256 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$8.03 - $14.82 $242,955 - $448,393	30,256 New	30,256 $254,000
Q2 2019 Aug 14, 2019	SELL	$11.88 - $16.94 $142,560 - $203,280	-12,000 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$17.44 - $17.95 $209,280 - $215,400	12,000 New	12,000 $215,000

2.56M

Ticker DTIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 110,818,000
Market Cap $539M
Description
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.